Neurotrope Tidbits

1. Company Presentation.
2. Bigger Capital Blog Posts: Our Second Alzheimer's Investment: Neurotrope.
3. Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study of Bryostatin-1 in Alzheimer's Disease including an important comment about safety.
4. Neurotrope Announces Positive Final Results From its Phase 2a Safety Study for the Treatment of Alzheimer's Disease.
5. Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimer's Disease.
6. NCI sponsored clinical trial and FDA Approved Compassionate Use protocols observations.
7. Neurotrope Patents Portfolio.
8. Capital invested in developing Bryostatin (BRNI invested $200 million) and running Neurotrope to date: $250 million.
9. Enterprise value about $25 million.
10. Capital Structure: 7 million shares, 780,000 warrants struck at $44.8, and 3.9 million warants struck at $12.8.
11. PHASE 2b DATA READOUT APRIL 2017.

Of Interest: An Alzheimer's Watershed Event on our Doorstep?

Michael Bigger. Follow me on Twitter and StockTwits.

Disclaimer.